HBV
MCID: HPT016
MIFTS: 65

Hepatitis B (HBV) malady

Categories: Skin diseases, Infectious diseases, Liver diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Hepatitis B

Aliases & Descriptions for Hepatitis B:

Name: Hepatitis B 38 12 52 41 42 14 69
Hepatitis B, Chronic 42 69
Chronic Hepatitis B 12 14
Hepatitis B Infection 12
Hepatitis B Chronic 52
Serum Hepatitis 12
Hbv 45

Classifications:



External Ids:

Disease Ontology 12 DOID:2043
NCIt 47 C3097
UMLS 69 C0019163

Summaries for Hepatitis B

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. hepatitis is an inflammation of the liver. one type, hepatitis b, is caused by the hepatitis b virus (hbv). hepatitis b spreads by contact with an infected person's blood, semen, or other body fluid. an infected woman can give hepatitis b to her baby at birth. if you get hbv, you may feel as if you have the flu. you may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. some people have no symptoms at all. a blood test can tell if you have it. hbv usually gets better on its own after a few months. if it does not get better, it is called chronic hbv, which lasts a lifetime. chronic hbv can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. there is a vaccine for hbv. it requires three shots. all babies should get the vaccine, but older children and adults can get it too. if you travel to countries where hepatitis b is common, you should get the vaccine. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b, chronic, is related to b-cell lymphomas and malignant glioma, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis B is LAMTOR5 (Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 5), and among its related pathways/superpathways are RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways and Toll-like Receptor Signaling Pathway. The drugs Adefovir Dipivoxil and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and skin, and related phenotype is mortality/aging.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted_by sexual contact, transmitted_by blood transfusions, and transmitted_by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 71 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It... more...

Related Diseases for Hepatitis B

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
id Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 29.6 F2 GGT1 GPT
2 malignant glioma 29.5 IFNA1 IFNA2
3 eclampsia 29.0 F2 GGT1 GPT SLC10A1
4 hemolytic-uremic syndrome 28.9 AFP ALB F2 GPT IFNA2 IFNG
5 hepatitis b reinfection following liver transplantation 11.8
6 hepatitis d 11.7
7 hepatitis 11.6
8 hepatocellular carcinoma 11.5
9 gianotti crosti syndrome 11.2
10 liver disease 11.2
11 membranous nephropathy 11.1
12 acrodermatitis 11.1
13 childhood hepatocellular carcinoma 11.1
14 hepatoblastoma 11.1
15 hepatitis c 10.4
16 viral hepatitis 10.4
17 tracheal calcification 10.4 GPT MBL2 TNF
18 congenital dyserythropoietic anemia 10.4 ALB TNF
19 hyperimmunoglobulin syndrome 10.3 IFNA1 IFNG TNF
20 anus leiomyosarcoma 10.3 APOBEC3G IFNA1 IFNG TNF
21 rosacea 10.3 ALB GPT IFNG
22 bladder sarcoma 10.3 ALB GPT TNF
23 hypertropia 10.3 ALB IFNG TNF
24 isolated growth hormone deficiency 10.3 ALB GPT IFNG
25 plummer's disease 10.3 ALB IFNG TNF
26 maxillary sinusitis 10.3 F2 GPT IFNA2
27 exophthalmos 10.3 GPT IFNA1 IFNA2 IFNG TNF
28 ovarian brenner tumor 10.3 IFNA1 IFNA2 IFNG TNF
29 rift valley fever 10.3 ALB IFNG TNF
30 fungal gastritis 10.3 IFNA1 IFNG TNF
31 familial progressive hyperpigmentation 10.3 F2 GPT
32 pulpitis 10.3 F2 IFNG TNF
33 low anorectal malformation 10.3 F2 IFNA1 TNF
34 mansonelliasis 10.3 ALB IFNG TNF
35 nondystrophic myotonia 10.3 ALB F2
36 liver inflammatory pseudotumor 10.3 ALB IFNG TNF
37 liver cirrhosis 10.3
38 goodpasture syndrome 10.3 IFNA1 IFNA2 IFNG MBL2 TNF
39 pulmonary eosinophilia 10.3 ALB IFNG MBL2 TNF
40 female infertility of uterine origin 10.3 ALB F2 GPT
41 ceruminoma 10.3 IFNA1 IFNA2
42 hepatitis c virus 10.3
43 patent foramen ovale 10.3 ALB GPT SLC10A1
44 kohler's disease 10.3 ALB F2 GPT
45 anterior foramen magnum meningioma 10.3 ALB IFNA1 IFNA2 IFNG TNF
46 infiltrating ureter transitional cell carcinoma 10.3 ALB F2 TNF
47 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.3 ALB F2 GPT
48 acute monocytic leukemia 10.3 ALB F2 GPT
49 ovarian papillary cystadenoma 10.2 ALB F2 IFNG
50 neonatal jaundice 10.2 IFNA1 IFNG TNF

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B

Symptoms & Phenotypes for Hepatitis B

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

UMLS symptoms related to Hepatitis B:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, icterus, nausea and vomiting, pruritus, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis B:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.44 AFP AIP ALB DDB1 DDX3X F2

Drugs & Therapeutics for Hepatitis B

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 602)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
2
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
3
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
4
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
5
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
6
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
7
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
8
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
9
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
12
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
13
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
14
Ethiodized oil Approved Phase 4,Phase 2,Phase 3 8008-53-5
15
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
16
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
17
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
18
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
19
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
20
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
21
Metformin Approved Phase 4,Phase 1 657-24-9 14219 4091
22
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
23
Pentoxifylline Approved, Investigational Phase 4,Phase 1 6493-05-6 4740
24
Colchicine Approved Phase 4 64-86-8 6167 2833
25
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 55981-09-4 41684
26
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
Isoniazid Approved Phase 4,Phase 2,Phase 3 54-85-3 3767
29
Pyrazinamide Approved Phase 4 98-96-4 1046
30
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
31
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
32 Simethicone Approved Phase 4,Phase 3
33
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
34
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 376348-65-1 3002977
35
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
36
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
37
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
38
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
39
Epinephrine Approved, Vet_approved Phase 4,Phase 1 51-43-4 5816
40
Lenograstim Approved Phase 4,Phase 3,Phase 1,Phase 2 135968-09-1
41
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
42
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
43
Ledipasvir Approved Phase 4,Phase 3,Phase 2 1256388-51-8 67505836
44
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Phase 1 1190307-88-0 45375808
45
chloroquine Approved, Vet_approved Phase 4,Phase 1 54-05-7 2719
46
Adalimumab Approved Phase 4 331731-18-1 16219006
47
Etanercept Approved, Investigational Phase 4 185243-69-0
48
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
49
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
50
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 2305)
id Name Status NCT ID Phase
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
3 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
4 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
5 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
6 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
7 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4
8 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
9 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
10 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4
11 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4
12 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4
13 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4
14 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4
15 Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B Unknown status NCT01926288 Phase 4
16 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4
17 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4
18 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4
19 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4
20 Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B Unknown status NCT01913431 Phase 4
21 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
22 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4
23 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4
24 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4
25 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4
26 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
27 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4
28 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
29 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4
30 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4
31 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4
32 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4
33 HBsAg Related Response Guided Therapy Unknown status NCT01456312 Phase 4
34 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4
35 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
36 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4
37 EFFORT Extension Study Unknown status NCT01529255 Phase 4
38 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4
39 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4
40 3E Extension Study Unknown status NCT01834508 Phase 4
41 A Two-year Study of Telbivudine in HBeAg Negative Hepatitis Unknown status NCT01521975 Phase 4
42 Antiviral Efficacy of Switching to ETV Plus TDF Unknown status NCT01597934 Phase 4
43 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
44 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4
45 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
46 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4
47 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy Unknown status NCT02081469 Phase 4
48 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
49 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4
50 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Genetic Tests for Hepatitis B

Anatomical Context for Hepatitis B

MalaCards organs/tissues related to Hepatitis B:

39
Liver, T Cells, Skin, Testes, Kidney, Eye, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

18
Liver

Publications for Hepatitis B

Articles related to Hepatitis B:

(show top 50) (show all 4468)
id Title Authors Year
1
Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area. ( 28493307 )
2017
2
Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA. ( 28077172 )
2017
3
A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine. ( 28060048 )
2017
4
A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques. ( 28082100 )
2017
5
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. ( 28529116 )
2017
6
Prevalence and risk factors for hepatitis B and C viruses in patients with leprosy. ( 28457830 )
2017
7
HMGB1-induced autophagy: a new pathway to maintain Treg cell function during chronic hepatitis B virus infection. ( 28082516 )
2017
8
Origin and evolutionary dynamics of Hepatitis B virus (HBV) genotype E in Madagascar. ( 28081689 )
2017
9
Improving access to health care for chronic hepatitis B among migrant Chinese populations: a systematic mixed methods review of barriers and enablers. ( 28092419 )
2017
10
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. ( 28075394 )
2017
11
Hypophosphatemia predicts a failure to recover from adefovir-related renal injury after dose reduction in lamivudine-resistant hepatitis B patients. ( 28079295 )
2017
12
Discovering potential serological biomarker for chronic Hepatitis B Virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis. ( 28079114 )
2017
13
Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. ( 28534427 )
2017
14
I^I'T cells are indispensable for IL-23-mediated protection against ConA-induced hepatitis in hepatitis B virus transgenic mice. ( 28092402 )
2017
15
Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection. ( 28084534 )
2017
16
Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. ( 28233741 )
2017
17
Noninvasive Assessment of Liver Fibrosis Stage Using Ultrasound-Based Shear Wave Velocity Measurements and Serum Algorithms in Patients With Viral Hepatitis B: A Retrospective Cohort Study. ( 28039877 )
2017
18
Des-I^ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study. ( 28085009 )
2017
19
Evaluation of hepatitis C, hepatitis B, and HIV virus Serology pandemic in thalassemia patients of Shahid Mohammadi Hospital of Bandar Abbas, Iran. ( 28461879 )
2017
20
Hypermethylation of the N-Myc Downstream-Regulated Gene 2 Promoter in Peripheral Blood Mononuclear Cells is Associated with Liver Fibrosis in Chronic Hepatitis B. ( 28202850 )
2017
21
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. ( 28078526 )
2017
22
Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma. ( 28127197 )
2017
23
ADVANCES WITH USING CRISPR/CAS-MEDIATED GENE EDITING TO TREAT INFECTIONS WITH HEPATITIS B VIRUS AND HEPATITIS C VIRUS. ( 28087399 )
2017
24
Hepatitis B virus X protein is capable of down-regulating protein level of host antiviral protein APOBEC3G. ( 28098260 )
2017
25
Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. ( 27902514 )
2017
26
Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ( 28063964 )
2017
27
Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line. ( 28088184 )
2017
28
Clinical features of hepatitis B and C virus infections, with high I+-fetoprotein levels but not hepatocellular carcinoma. ( 28079817 )
2017
29
Early-age hepatocellular carcinoma associated with hepatitis B infection in South America. ( 28532694 )
2017
30
Involvement of viperin in prevention of intrauterine transmission of hepatitis B virus. ( 27943419 )
2017
31
A Effects of interleukin-4 and interleukin-12B gene polymorphisms on hepatitis B virus vaccination. ( 28051794 )
2017
32
Glucose-regulated protein 78 demonstrates antiviral effects but is more suitable for hepatocellular carcinoma prevention in hepatitis B. ( 28407787 )
2017
33
Promoting the Awareness of Hepatitis B Virus Screening in Patients With Lymphoma. ( 27661750 )
2016
34
Inhibition of hepatitis B virus replication by a dNTPase-dependent function of the host restriction factor SAMHD1. ( 27179347 )
2016
35
Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis. ( 28032257 )
2016
36
Tumor Necrosis Factor Alpha 308 G/A Single Nucleotide Polymorphism and Susceptibility to Hepatocellular Carcinoma Via Hepatitis B Infection. ( 27509979 )
2016
37
Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection. ( 26701850 )
2016
38
Role of IL-10 polymorphisms in susceptibility to hepatitis B virus-related hepatocellular carcinoma. ( 27050962 )
2016
39
Brucellosis With Multi-Organ Involvement in a Patient With History of Composite Aortic Graft and Hepatitis B. ( 28033700 )
2016
40
Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication. ( 27594346 )
2016
41
The possible impact of sortilin in reducing HBsAg expression in chronic hepatitis B. ( 26331452 )
2016
42
Investigation of 1377C/T polymorphism of the Toll-like receptor 3 among patients with chronic hepatitis B. ( 27314608 )
2016
43
Hepatitis B Leading to Megaloblastic Anemia and Catastrophic Peripheral Thrombocytopenia. ( 28043314 )
2016
44
Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. ( 28077916 )
2016
45
Hypertension in the liver clinic - polyarteritis nodosa in a patient with hepatitis B. ( 26989675 )
2016
46
Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B? ( 27499150 )
2016
47
Digital ischemic necrosis with cryoglobulinemia associated with hepatitis B infection. ( 27857479 )
2016
48
Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus I+-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. ( 27070780 )
2016
49
Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. ( 26756996 )
2016
50
Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. ( 27895405 )
2016

Variations for Hepatitis B

Expression for Hepatitis B

Search GEO for disease gene expression data for Hepatitis B.

Pathways for Hepatitis B

Pathways related to Hepatitis B according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.5 DDX3X IFNA1 IFNA2 IFNG TNF
2
Show member pathways
12 DDB1 DDX3X IFNA1 IFNA2 IFNG LAMTOR5
3 11.96 IFNA1 IFNA2 IFNG TNF
4
Show member pathways
11.69 ALB F2 GGT1 IFNG TNF
5
Show member pathways
11.67 IFNA1 IFNA2 IFNG TNF
6 11.53 IFNA2 IFNG TNF
7 11.44 IFNA1 IFNA2 IFNG
8 11.23 AIP IFNG TNF
9 11.14 AFP ALB F2
10 11.06 IFNA1 IFNA2 RARB

GO Terms for Hepatitis B

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AFP ALB DDX3X F2 IFNA1 IFNA2
2 extracellular space GO:0005615 9.4 AFP ALB CPD DDB1 F2 GGT1

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 ALB DDB1 DDX3X LAMTOR5 RARB
2 innate immune response GO:0045087 9.91 APOBEC3G DDX3X IFNA1 IFNA2 MBL2
3 defense response to virus GO:0051607 9.76 APOBEC3G IFNA1 IFNA2 IFNG
4 response to virus GO:0009615 9.67 DDX3X IFNG LAMTOR5 TNF
5 positive regulation of viral genome replication GO:0045070 9.5 DDB1 DDX3X NR5A2
6 positive regulation of chemokine biosynthetic process GO:0045080 9.49 IFNG TNF
7 positive regulation of programmed cell death GO:0043068 9.48 RARB TNF
8 negative regulation of viral process GO:0048525 9.43 APOBEC3G MBL2
9 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.4 IFNG TNF
10 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.33 IFNA1 IFNA2 IFNG
11 positive regulation of vitamin D biosynthetic process GO:0060557 9.26 IFNG TNF
12 negative regulation of growth of symbiont in host GO:0044130 9.13 IFNG MBL2 TNF
13 humoral immune response GO:0006959 8.92 IFNA1 IFNA2 IFNG TNF

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNA1 IFNA2 IFNG TNF

Sources for Hepatitis B

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31